Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Less can be more when treating infective endocarditis. The POET II trial found that stopping antibiotics once patients stabilize — rather than completing a fixed 4–6 week course — gave patients significantly more time alive and antibiotic-free, with no meaningful difference in overall safety. Over 50% of endocarditis patients may be candidates for this personalized approach.
The POET II trial, presented at the European Society of Cardiology Congress and published simultaneously in The New England Journal of Medicine, is challenging a long-standing dogma in cardiology: that left-sided infective endocarditis always requires a full 4–6 weeks of antibiotics. The trial enrolled 508 patients infected with Staphylococcus aureus, Enterococcus faecalis, or streptococcus species, randomizing them to either a response-tailored strategy (stopping antibiotics once stabilization criteria were met) or standard fixed-duration therapy.
The results? Patients in the tailored group gained a meaningful edge — 13 more days alive without antibiotic therapy — while remaining just as safe overall. Building on POET I, which showed that stepping down to oral antibiotics was associated with a 39% reduction in mortality after 5 years, POET II reinforces that personalizing treatment after stabilization is both effective and safe.
By the Numbers:
Why it matters: Prolonged antibiotic courses carry real risks — side effects, resistance, and hospital burden. A personalized, response-guided approach could safely reduce treatment duration for a significant proportion of patients with this serious heart infection.
